One of the most fundamentally critical elements of diagnostic histopathology is the ability to suspend all cellular activity in tissues and prevent degradation, and secondly, to process specimen in a manner that facilitates subsequent steps such as microtomy and staining.
Kristalyn Gallagher, DO, Kevin Chen, MD, and Shawn Gomez, EngScD, in the UNC School of Medicine have developed an AI model that can predict whether or not cancerous tissue has been fully removed from the body during breast cancer surgery.
In a recent study, researchers at the Wellcome/EPSRC Centre for Interventional and Surgical Sciences and the Department of Computer Science at University College London investigated the minimum spatial and digital sampling resolution required for accurate binary classification of breast histology images into benign or malignant categories.
PRINCETON, NJ and DUBLIN, IRELAND / ACCESSWIRE / September 14, 2023 / Deciphex, a trailblazer in digitizing and networking global pathologists, has joined forces with Xybion, a global leader in unified cloud software solutions for regulated industries. This collaboration marks a significant milestone in the healthcare technology sector, aimed at enhancing the pathology reporting processes and optimizing workflow efficiency for pathologists working in the pharmaceutical and biotech industries.The collaboration between Deciphex and Xybion introduces a groundbreaking integration that offers a seamless synergy between their platforms. This integration provides real-time digital slide availability during pathology data entry. In addition, for Pathology Peer Review, embedded finding searching, filtering and viewing results in accelerated and higher quality processes. By combining Patholytix’s scalable digital pathology management solution with Xybion’s unified cloud software ecosystem, professionals in the pharmaceutical and biotech industries can streamline their operations and focus on delivering improved regulatory submissions.Patholytix offers a scalable, GLP-compliant digital pathology management solution that includes a Viewer, Image QC, Storage, AI Decision support, and synchronized data capture. This comprehensive solution accelerates drug development timelines, enhances image quality control, and offers AI-driven decision support for critical assessments. This collaboration with Xybion further enhances the capabilities of Patholytix by seamlessly integrating it into Xybion’s unified cloud software ecosystem.By collaborating with Xybion, this suite of advanced features is bolstered by Xybion’s expertise in compliance, quality management, and unified cloud solutions.“We are excited to collaborate with Deciphex and integrate Patholytix into our unified cloud software solutions,” says Dr. Pradip Banerjee, Chairman and CEO of Xybion Digital. “This collaboration perfectly aligns with our commitment to provide innovative solutions that optimizes workflows, enhances compliance, and drives efficiency across regulated industries.”With the collaboration between Deciphex and Xybion, pathologists, healthcare providers, and researchers can expect an enhanced experience, with seamless transitions between platforms, faster decision-making, and a greater focus on delivering high-quality products for patient care.Together, Deciphex and Xybion streamline pathological studies with the following capabilities:Study planningProtocol managementStudy execution and data collectionQuality, compliance, and deviation managementData ManagementVisualizations for ongoing studiesDigital Slide Viewer, Image QC, Storage, AI Decision support, and synchronized data capture.The convergence of Deciphex’s Patholytix digital pathology management system with Xybion’s Pristima XD, a unified total preclinical research and development software is poised to further advance preclinical research, toxicologic pathology studies, and accelerate the development of life saving pharmaceuticals.For more information about the collaboration between Deciphex and Xybion and the benefits it offers, please visit https://www.deciphex.com and https://www.xybion.com/.About DeciphexDeciphex is a pioneering company at the forefront of the digital transformation of pathology. By networking with global pathologists and leveraging AI-driven solutions, Deciphex accelerates certainty in pathology reporting, ultimately enhancing patient care and advancing drug development. For more information, visit https://www.deciphex.com.About Xybion Digital Inc.Xybion is a global SaaS company that helps enterprise life sciences organizations accelerate new drug development into approved medicines that may save lives and keep employees safe. We digitize drug research and development, laboratory testing, regulatory approvals, and pharmaceutical manufacturing on a single, unified cloud platform that is cost-effective, ready to deploy, and easy to use. Xybion has over 160 clients in 29 countries using its low-code software to accelerate timelines, improve compliance, expand capacity, minimize operating risks, and reduce expenses while keeping employees safe.Learn more about Xybion at https://www.xybion.com/For further information:For more information regarding Xybion Digital Inc., please contact Pradip Banerjee, Chief Executive Officer, PB*******@****on.com, 609-512-5790 x122For more information regarding Deciphex Ltd., please contact Katie Higgins, Global Marketing Manager, ka***********@******ex.com, +35312210842Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Forward-Looking StatementsCertain statements (“forward-looking statements“) in this news release may contain forward-looking information concerning relating to the release of financial results, plans related to the Company’s business and other matters that may occur in the future, made as of the date of this news release. In making the forward-looking statements included in this news release, the Company has applied several material assumptions, including with respect to the timing of such release. Although management considers these assumptions to be reasonable based on information available to it, they may prove to be incorrect.Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors which could cause actual events or results to differ from those expressed or implied by the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important factors could cause the actual outcomes to differ materially from the expectations expressed in them. Such factors include, among others, the risks described in disclosure documents filed by the Company on SEDAR. There can be no assurance that forward-looking statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as otherwise required by applicable securities legislation.This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.SOURCE: Accesswire
In tissue diagnostics, where timely and accurate diagnosis can be a matter of life and death, advancements in artificial intelligence (AI) are reshaping possibilities. On September 7, 2023, healthcare tech firm Paige teamed up with Microsoft to pioneer advanced AI-driven digital pathology solutions for revolutionizing cancer diagnosis and care. Enter Virchow, a deep neural network equipped with a staggering 632 million parameters.
Tribun Health, a leading innovator in the field of digital pathology, is delighted to announce the completion of its Series B financing round, securing an investment of €15 million. This financing round is led by the Fonds Patient Autonome managed by Bpifrance, alongside several new investors, including Owkin and Vivalto Family, with whom the....
This episode’s guest Geert Litjens – a member of the computational pathology group at Radboud University Medical Center explains how semi-supervised and weekly supervised artificial intelligence-based image analysis can help pathologists do better, more time-efficient, and data-efficient digital pathology.
In digital pathology, where precision and accuracy are paramount, the role of automated quality control (QC) solutions is becoming increasingly vital. Automated quality control solutions identify slide and tissue artifacts so the laboratory can identify affected slides, creating efficiency benefits for the workflow and improving data quality for research and analysis.
Aiosyn, a medical software company specializing in AI-powered pathology solutions, has announced the release of an AI kidney suite designed to advance research in the field of renal disease. Leveraging cutting-edge deep learning technology, this innovative solution provides biopharma and research organizations with powerful tools for analyzing kidney structures and quantifying lesions that impact kidney health. Aiosyn’s kidney AI suite marks yet another significant milestone for the company, following the recent launch of Aiosyn Mitosis Research.
Owkin and Tribun Health announce a strategic partnership to advance the development and global deployment of Artificial Intelligence (AI) Diagnostic and Research solutions for pathology departments and pharma companies. The non-exclusive partnership will see the integration of Owkin’s groundbreaking AI diagnostics into Tribun Health’s ‘Best in KLAS’ software platform, CaloPix, expanding its portfolio of AI solutions. Moreover, Owkin customers and users will be able to benefit from Tribun Health’s fully integrated software platform for research that streamlines pathology data workflows. This research platform, called EyeDo, is the heir to the Keen Eye acquisition made in 2022.
